Dyadic International Inc
NASDAQ:DYAI

Watchlist Manager
Dyadic International Inc Logo
Dyadic International Inc
NASDAQ:DYAI
Watchlist
Price: 1.93 USD 15.57% Market Closed
Market Cap: 56.9m USD
Have any thoughts about
Dyadic International Inc?
Write Note

Dyadic International Inc
Research & Development

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Dyadic International Inc
Research & Development Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Research & Development CAGR 3Y CAGR 5Y CAGR 10Y
Dyadic International Inc
NASDAQ:DYAI
Research & Development
-$2.4m
CAGR 3-Years
30%
CAGR 5-Years
9%
CAGR 10-Years
-24%
Abbvie Inc
NYSE:ABBV
Research & Development
-$7.9B
CAGR 3-Years
-4%
CAGR 5-Years
-9%
CAGR 10-Years
-10%
Gilead Sciences Inc
NASDAQ:GILD
Research & Development
-$5.5B
CAGR 3-Years
-4%
CAGR 5-Years
10%
CAGR 10-Years
-9%
Amgen Inc
NASDAQ:AMGN
Research & Development
-$5.8B
CAGR 3-Years
-7%
CAGR 5-Years
-8%
CAGR 10-Years
-3%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Research & Development
-$3.5B
CAGR 3-Years
-7%
CAGR 5-Years
-15%
CAGR 10-Years
-14%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Research & Development
-$4.9B
CAGR 3-Years
-20%
CAGR 5-Years
-14%
CAGR 10-Years
-15%
No Stocks Found

Dyadic International Inc
Glance View

Market Cap
57.1m USD
Industry
Biotechnology

Dyadic International, Inc. engages in developing a gene expression platform for producing commercial quantities of industrial enzymes and other proteins. The company is headquartered in Jupiter, Florida and currently employs 7 full-time employees. The company went IPO on 2004-11-05. The firm is focused on developing C1 platform for use in human and animal pharmaceutical applications across the world. The C1 platform technology is based on the Myceliopthora thermophila fungus, which the Company named it as C1. The C1 gene expression platform is used in the discovery, development and manufacturing of biologic medicines and vaccines. The C1 technology is a fungal expression system for gene discovery, development, and production of enzymes and other proteins. The C1 technology is commercially available solutions to uptake genes and develop industrial processes to produce volumes of enzymes and other protein products. The firm is also working on COVID-19 related vaccine and antibody opportunities, including COVID-19 vaccine candidate, DYAI-100.

DYAI Intrinsic Value
2.08 USD
Undervaluation 7%
Intrinsic Value
Price

See Also

What is Dyadic International Inc's Research & Development?
Research & Development
-2.4m USD

Based on the financial report for Sep 30, 2024, Dyadic International Inc's Research & Development amounts to -2.4m USD.

What is Dyadic International Inc's Research & Development growth rate?
Research & Development CAGR 10Y
-24%

Over the last year, the Research & Development growth was 22%. The average annual Research & Development growth rates for Dyadic International Inc have been 30% over the past three years , 9% over the past five years , and -24% over the past ten years .

Back to Top